非小细胞肺癌患者对吉非替尼耐药的可能相关因素及预测因子

Possible associated factors and predictors of gefitinib resistance in patients with non-small cell lung cancer

在我国,肺癌的发病率及病死率居各种恶性肿瘤之首,多数患者在发现肺癌时已失去最佳手术时机。随着分子生物医学的发展,根据肺癌基因突变类型选用合适的分子靶向药物受到临床青睐,多项大型研究表明其在缓解率(response rate,RR)、无进展生存期(progress free survival,PFS)及生活质量等方面优于化疗。在肺癌靶向药物中,最常用、临床应用数据最多的是第1代表皮生长因子受体-酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitor,EGFR-TKI)中的吉非替尼,但不可避免的是,患者会在数月至数年内出现耐药问题。本文分析了在吉非替尼耐药的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中与产生耐药的可能相关因素,并推测预测因子,旨在为临床上对靶向药的选择给予指导。

In China,the incidence and mortality of lung cancer ranks the top of various malignancies,and most patients have lost the best surgical opportunity for lung cancer.With the development of molecular biomedicine,the choice of appropriate molecular targeting drugs according to the type of lung cancer gene mutation is favored by the clinic.Many large studies have shown that it is superior to chemotherapy in terms of response rate(RR),progress free survival(PFS)and quality of life.Among lung cancer targeting drugs,the most commonly used,and the most clinical application date are gefitinib in I-generation epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI).This review summarizes the analysis of possible related factors associated with the generation of drug resistance in patients with non-small cell lung cancer(NSCLC)with gefitinib resistance,presumably predictive factors,hoping to guide the selection of targeted drugs clinically.